Q-Gen is currently working with Alloplex Biotherapeutics on developing a cellular therapy to treat cancer where activated cells target tumours with no harm inflicted on normal tissue.

Alloplex CEO and Founder, Frank Borriello says the company partnered with Q-Gen for its expertise, its ability to manufacture cells according to GMP (good manufacturing practice) conditions, and its regulatory approval status.

“Working with them we’ve been able to take the asset from the pre-clinical stage to now having treated over 25 patients and the results are spectacular,” said Mr Borriello.